Niemann-Pick type C (NPC) disease is an autosomal recessive lysosomal storage disorder caused by mutations in the NPC1 or NPC2 genes. Loss of function mutations in either gene disrupt intracellular lipid trafficking and lead to a clinically heterogeneous phenotype that invariably includes neurological dysfunction and early death. The mechanism by which impaired lipid transport leads to neurodegeneration is poorly understood. Here we used mice with a conditional null allele to establish the timing and cell type that underlie neurodegeneration due to Npc1 deficiency. We show that global deletion of Npc1 in adult mice leads to progressive weight loss, impaired motor function and early death in a time course similar to that resulting from germline deletion. These phenotypes are associated with the occurrence of characteristic neuropathology including patterned Purkinje cell loss, axonal spheroids and reactive gliosis, demonstrating that there is not a significant developmental component to NPC neurodegeneration. Furthermore, we show that these same changes occur when Npc1 is specifically deleted only in neurons, establishing that neuronal deficiency is sufficient to mediate central nervous system (CNS) disease. In contrast, astrocyte-specific deletion does not impact behavioral phenotypes, CNS histopathology or synaptic function. We conclude that defects arising in neurons, but not in astrocytes, are the determining factor in the development of NPC neuropathology.
INTRODUCTION
Niemann-Pick type C disease (NPC) is a childhood-onset neurodegenerative disorder characterized biochemically by the accumulation of unesterified cholesterol and glycosphingolipids in late endosomes and lysosomes (1) . Loss of function mutations in the NPC1 gene, which encodes a multipass transmembrane protein that is essential for mobilizing cholesterol from the endolysosomal system, disrupt intracellular lipid trafficking in 95% of NPC patients (2 -4) . The resulting disease exhibits progressive neuropathology in which intracellular lipid accumulation, abnormally swollen axons, neuron loss and demyelination underlie the occurrence of cognitive impairment, ataxia, seizures and early death (5) . Although disease-causing mutations were identified over a decade ago, it remains unknown how disruption of intracellular lipid transport leads to the severe, progressive neurological impairment characteristic of NPC.
Insights into the pathogenesis of central nervous system (CNS) disease have been gleaned from studies of NPC mouse models. Recent pre-clinical therapeutic trials in mice with an insertional mutation that abolishes Npc1 gene function highlight cyclodextrin as a promising therapeutic candidate. Cyclodextrin circumvents the requirement for Npc1 to clear stored lipids from diseased cells (6) , and several studies have shown that a single injection at postnatal day 7 markedly prolongs the lifespan of mutant mice (7 -9) . In contrast, injections at later ages are less effective (7 -9) . Although cyclodextrin's therapeutic mechanism remains incompletely understood, this time-sensitive beneficial effect raised the possibility of a critical developmental window for disease.
Much effort has also focused on defining the cell types responsible for CNS degeneration, with the expectation that this is an important first step toward identifying pathogenic mechanisms. Following the demonstration that transgenic expression of Npc1 predominantly in the CNS diminishes disease severity in Npc1 null mice (10) , several models systems were used to explore the contributions of neurons and glia. Transgenic rescue experiments in NPC mouse and Drosophila models (11, 12) , and co-culture experiments with neurons and glia (13) , raised the possibility that astrocytes contribute to neurodegeneration. However, conditional deletion of Npc1 only in cerebellar Purkinje cells and an analysis of chimeric mice demonstrate that Npc1 deficiency triggers cell autonomous Purkinje cell loss (14, 15) . Furthermore, recent studies show that transgenic expression of Npc1 in neurons, but not astrocytes, delays CNS disease, indicating that Npc1 expression by neurons is necessary for nervous system function (16) . Whether neuronal or glial deficiency of Npc1 is sufficient to cause NPC neuropathology has not been addressed previously.
To determine the extent to which Npc1 deficiency during CNS development is necessary for NPC neuropathology and to help define the cell type critical for disease pathogenesis, we used mice containing a conditional null allele of the Npc1 gene. By employing various Cre lines, we achieved deletion of the Npc1 gene in a spatial-and temporal-specific manner. Our findings demonstrate that deletion of Npc1 in the adult is sufficient to cause disease, and show that neurons, but not astrocytes, are the critical cell type for NPC neurodegeneration.
RESULTS

Adult deletion of Npc1 recapitulates NPC neuropathology
We first sought to determine the extent to which Npc1 deficiency during CNS development is necessary for NPC neuropathology. To answer this question, we utilized mice with a floxed allele of the Npc1 gene (Npc1 flox ), in which exon 9 is flanked by loxP sites. We have shown previously that Cremediated deletion of exon 9 yields a null allele that is functionally indistinguishable from the spontaneous null mutant found in the widely used npc nih (Npc1 2/2 ) model (14) . These mice were bred with transgenic animals expressing a tamoxifen-regulated Cre recombinase under the control of the cytomegalovirus (CMV) promoter (Cre-ER TM ) (17) . Our breeding strategy generated littermates expressing Cre recombinase that were compound heterozygotes of the conditional Npc1 allele. To induce Cre-mediated deletion of experimental (Npc1 flox/2 , Cre-ER TM+ ) and control (Npc1
, Cre-ER TM+ ) mice, both groups were injected with tamoxifen at 6 weeks, an age at which mice are sexually mature and have a fully developed CNS. Following injections, we verified diminished Npc1 expression in the brain by western blot (Fig. 1A) . Similar to mice with germline deletion (Npc1 , Cre-ER TM+ mice (adult deletion) with that of Npc1 △/2 mice (germline deletion) revealed slightly longer survival (Fig. 1E) , a finding that may reflect differences in the extent of gene deletion between these groups.
Based on prior analyses of the neuropathology of mice in which Npc1 deletion occurred in the germline, we next determined whether similar changes occurred following adult deletion. Calbindin staining of sagittal midline cerebellar sections revealed progressive anterior-to-posterior Purkinje cell loss in tamoxifen-treated Npc1 flox/2 , Cre-ER TM+ mice ( Fig. 2A) . This patterned Purkinje cell loss has been documented previously in Npc1 2/2 and Npc1 △/2 mice (14, 18) . Quantification of Purkinje cell density demonstrated that the rate of neuron loss fits well into a model incorporating a plateau followed by exponential decay (Fig. 2B) (Fig. 2C) . Quantification of Purkinje cell density by lobule revealed selective vulnerability of Purkinje cell subpopulations, with cells in anterior lobules degenerating early and those in posterior lobules exhibiting resistance to the toxicity of Npc1 deficiency (Fig. 2D ). This survival of Purkinje cells in posterior lobules occurred despite the accumulation of unesterified cholesterol (Fig. 2E) . All of these findings are similar to those documented in Purkinje cellspecific Npc1 null mice (Npc1 flox/2 , Pcp2-Cre + ), further supporting the notion that Purkinje cell loss is independent of events during development (14) . In addition to cerebellar pathology, widespread axonal spheroids, secondary demyelination, microgliosis and astrocytosis were also present in Npc1 flox/2 , Cre-ER TM+ mice (Fig. 2F) . We conclude that deletion of Npc1 in the adult CNS is sufficient to cause disease and that there is not a significant developmental component to NPC neuropathology.
Astrocyte-specific deletion of Npc1 does not lead to CNS pathology
We next sought to establish the contribution of distinct CNS cell populations to NPC neuropathology, and began by deleting Npc1 only in astrocytes. To achieve astrocyte-specific deletion, we used mice expressing a tamoxifen-regulated Cre recombinase under the control of the human glial fibrillary acidic protein (GFAP) promoter (GFAP-CreER T2+ ) (19) . To avoid confounding effects due to GFAP expression by neuronal precursors during development (20) , Cre activation was induced by tamoxifen injections at 6 weeks. We confirmed gene deletion by staining brain sections with filipin, a fluorescent dye that marks accumulations of unesterified cholesterol (21) . By performing GFAP and filipin co-staining, we confirmed that Npc1 flox/2 , GFAP-CreER T2+ mice, but not Npc1 flox/+ , GFAP-CreER T2+ controls, contained widespread filipin-positive astrocytes throughout the brain (Fig. 3A-C) .
Despite the occurrence of efficient recombination, phenotype analysis did not reveal any differences between astrocytespecific null mice (Npc1 flox/2 , GFAP-CreER T2+ ) and their littermate controls (Npc1
. Astrocytespecific null mutants gained weight normally ( Fig. 4A and B), showed unimpaired motor performance ( Fig. 4C ) and exhibited normal survival (Fig. 4D) . Similarly, histological examination did not uncover abnormalities in the astrocytespecific null mutants. Compared with controls, there was no Purkinje cell loss in the cerebellar midline, even at 48 weeks ( Fig. 5A and B), nor was there formation of axonal spheroids or evidence of demyelination (Fig. 5C ). Additionally, we did not detect activated astrocytes or microglia ( We considered the possibility that Npc1 deletion in astrocytes impaired neuron function without triggering morphological hallmarks of neuron loss. To test this possibility, we focused on cerebellar glial cells in mice aged ,4 weeks. To accomplish this, we generated another cohort of Npc1 , GFAP-CreER T2+ controls which were injected with tamoxifen at postnatal days 12 and 14. As with mice receiving tamoxifen at 6 weeks, these astrocyte-specific null mice showed no deficits in weight, motor function or survival (Supplementary Material, Fig. S3 ).
The synapses of cerebellar parallel fibers onto Purkinje cells are strongly wrapped by Bergmann glia, specialized astrocytes in the cerebellum that express a high density of glutamate transporters (22) . We determined whether the absence of ) is shown by dashed line (14) .
Npc1 triggered glial dysfunction that altered the handling of glutamate at the parallel fiber-Purkinje neuron synapse in cerebellar slices. We assessed glutamatergic synaptic responses using whole-cell patch-clamp recordings from Purkinje neurons in the presence of 50 mM picrotoxin to block inhibitory post-synaptic currents. In response to stimulation of parallel fibers in the molecular layer, we elicited excitatory post-synaptic currents (EPSCs) that increased in amplitude , GFAP-CreER T2 mice. Since inhibiting glial glutamate transporters slows the decay of parallel fiber EPSCs when many nearby parallel fibers are simultaneously activated (23), we also determined whether the EPSC decay time constant increased with increasing stimulus strength. However, we detected no significant slowing of EPSC decay with increasing stimulation of parallel fibers (Fig. 5F ). As Bergmann glia may influence presynaptic transmitter release (24), we determined whether paired-pulse facilitation was altered in the astrocyte-specific null mutants; no difference was detected ( Fig. 5G and H) . These electrophysiologic studies suggest that the loss of Npc1 in Bergmann glia was not associated with functional alterations in synaptic transmission. Taken together, our analyses indicate that Npc1 deficiency in astrocytes is not a prime contributor to the NPC disease phenotype.
Deletion of Npc1 in neurons is sufficient to cause neurodegeneration
The fact that mice were not affected by deletion of Npc1 in astrocytes led us to test whether neurodegeneration in NPC is heavily dependent upon toxicity within neurons. To accomplish neuron-specific Npc1 deletion, we used transgenic mice expressing Cre recombinase under the control of the Synapsin1 promoter (Syn1-Cre) (25) . In these mice, Cre is abundantly and specifically expressed in neurons during late embryonic development in a wide range of brain regions, but is minimally expressed in cerebellar Purkinje cells. Filipin and NeuN co-staining verified that Npc1 flox/2 , Syn1-Cre + mice, but not Npc1 flox/+ , Syn1-Cre + controls, developed filipin-positive neurons in multiple brain regions, including the cortex (Fig. 6A) and brainstem (Fig. 6B) . Histological examination of liver sections from Npc1 flox/2 , Syn1-Cre + mice did not reveal an accumulation of foamy macrophages (Fig. 6C) , consistent with reports that Cre expression is not leaky in visceral organs. Neuron-specific deletion of Npc1 reproduced the phenotypic features observed following global gene deletion. Npc1 flox/2 , Syn1-Cre + mice, but not littermate controls, developed progressive weight loss ( Fig. 7A and B) , motor deficits in both balance beam (Fig. 7C) and rotarod (Fig. 7D ) tests, and early death, with an average lifespan of 105 days (Fig. 7E) .
The development of motor impairment occurred in the absence of Purkinje cell degeneration. Histological examination of sagittal midline cerebellar sections revealed no Purkinje cell loss in end-stage Npc1 flox/2 , Syn1-Cre + mice at 16 weeks ( Fig. 8A and B) . This finding is consistent with the fact that the Syn1-Cre transgene is poorly expressed by Purkinje cells (25) . The occurrence of motor deficits in these animals indicates that pathology elsewhere in the nervous system is sufficient to cause this phenotype. In support of this conclusion, Npc1 flox/2 , Syn1-Cre + mice, but not Npc1 flox/+ , Syn1-Cre + controls, showed severe axonal pathology with frequent axonal spheroids in the brainstem, loss of myelinated fibers in the corpus callosum and activated microglia and astrocytes in many brain regions (Fig. 8C , Supplementary Material, Fig. S1B ). We conclude that deletion of Npc1 in neurons is sufficient to recapitulate the neuropathological features of NPC mice.
DISCUSSION
Here we used Npc1 conditional null mutant mice to achieve global deletion of the Npc1 gene in adults as well as restricted deletion in specific CNS cell types, including astrocytes and neurons. Our findings demonstrate that deletion of Npc1 in adults is sufficient to recapitulate the disease phenotypes of weight loss, motor deficits and early death. Pathological changes in the CNS of mice following adult deletion were similar to those triggered by germline deficiency and included patterned Purkinje cell loss, axonal pathology and glial activation. Our findings indicate that an impairment of developmental events is not necessary for the occurrence of CNS pathology. Furthermore, our data establish that deletion of Npc1 in neurons, but not in astrocytes, is sufficient to cause neurodegeneration. The observation that neuronal loss of Npc1 is the primary cause of neuropathology in mice identifies neurons as the critical target cell for future therapeutic interventions.
There has been significant interest in the potential role of astrocytes in the development of NPC neuropathology since the initial observation that these cells robustly express the NPC1 protein (26) (27) (28) . Astrocytes are an abundant glial cell in the CNS with diverse functions in synaptic transmission (29) , neuroinflammation (30) and lipid homeostasis (31) . Astrocytic processes are closely associated with synapses, , GFAP-CreER T2+ mice). Data are mean + SEM, P . 0.05. and these cells both promote synaptogenesis by secreting factors, such as lipoproteins (32) and thrombospondins (33) , and facilitate synaptic function by contributing to the clearance of extracellular neurotransmitters (34) . Astrocytes are also capable of releasing a variety of cytokines, and these inflammatory mediators have been implicated in the development of CNS disease (35) . While Npc1 deficiency in astrocytes in vitro results in the sequestration of cholesterol in late endosomes and lysosomes, it does not impair the secretion of sterols, including cholesterol (36, 37) . Nonetheless, given the importance of astrocytes in maintaining brain homeostasis, they have been implicated in NPC neurodegeneration. This notion was supported by prior studies of transgenic mice in which GFAP-promoter driven expression of an Npc1 transgene extended lifespan of Npc1 2/2 mice (11). However, a recent analysis of mice expressing a tagged Npc1 transgene whose expression was clearly restricted to astrocytes showed no phenotypic rescue (16). Here we determined the extent to which deletion of Npc1 only in astrocytes contributes to CNS disease. Our data show that astrocytespecific null mutants (Npc1
, GFAP-CreER T2+ ) display no phenotypic abnormalities, histopathological changes or evidence of synaptic dysfunction. These unexpected findings demonstrate that Npc1 deficiency in astrocytes is not sufficient to mediate disease. Furthermore, the observation that astrocyte-specific null mutants show no glial activation is consistent with prior work, suggesting that gliosis is the consequence, but not the cause of neuronal dysfunction and death.
In marked contrast, neuronal restricted deletion of Npc1 recapitulates many of the phenotypic and pathological features exhibited by mice with global, germline deficiency. The occurrence of motor impairment in Npc1 flox/2 , Syn1-Cre + mice was particularly interesting since this occurred in the setting of only limited Cre expression by cerebellar Purkinje cells (25) . As such, Npc1 flox/2 , Syn1-Cre + mice displayed balance beam and rotarod deficits without concurrent Purkinje cell loss. Complementing these findings is our prior analysis of Purkinje cell-specific null mutants that demonstrate motor impairment without other features of the NPC phenotype (14) . We conclude that although Purkinje cell loss is sufficient to mediate motor dysfunction, it is not required for it, and pathology elsewhere in the brain likely accounts for this disease manifestation in mice expressing the Syn1-Cre transgene. The brainstem, thalamus, cortex and subcortical white matter are abnormal in these mutants, and several of these sites may contribute to the observed phenotype.
The data reported here extend our understanding of disease mechanisms underlying the development of NPC neuropathology. We conclude that neuron dysfunction and loss are the consequence of cell autonomous processes, a notion originally suggested by an analysis of Npc1-deficient Purkinje cells (14, 15) and supported by neuron-restricted transgenic rescue experiments (16) . We find no evidence that astrocytes are primary contributors to disease pathology, despite the existence of multiple potential mechanisms that made them attractive candidates. Finally, our data support the emerging concept that glial reaction and neuroinflammation occur secondary to neuronal injury. Whether the inflammatory mediators they produce contribute to the pathogenic cascade remains to be defined. Taken together, our analysis establishes a critical role for neuronal deficiency of Npc1 in the development of CNS disease, and compels us to search for therapeutic targets that mediate cell autonomous neurodegeneration.
MATERIALS AND METHODS
Mice
Npc1
flox/flox and Npc1 △/2 mice were generated as previously described (14) . Tamoxifen-inducible CMV-Cre mice (Cre-ER TM+ ) (#004682) (17), Pcp2-Cre mice (#004146) (38) and Sny1-Cre mice (#003966) (25) were from the Jackson Laboratories.
Tamoxifen-inducible GFAP-Cre mice (GFAP-CreER T2+ ) (19) were from the Mutant Mouse Regional Resource Center (#016992-MU/H). All mouse strains were backcrossed to C57BL6/J for .10 generations, except Syn1-Cre mice which were backcrossed seven generations. Animal use and procedures were approved by the University of Michigan Committee on the Use and Care of Animals.
Tamoxifen induction
Tamoxifen (Sigma) was dissolved in corn oil (Sigma) at 20 mg/ml and stored at 2208C in the dark. The stock solution was warmed to 378C before injection. Adult mice were injected intraperitoneally with 3 mg (for Cre-ER TM+ mice) or 5 mg (for GFAP-CreER T2+ mice) tamoxifen per 40 g body weight for five consecutive days at 6 weeks. Pups were injected intraperitoneally with 5 mg tamoxifen per 40 g body weight at postnatal days 12 and 14. 
Phenotype analysis
Motor function was measured using the balance beam and rotarod tests as described previously (14) .
Western blot
Brain lysates were homogenized in radio-immunoprecipitation assay buffer (Thermo Scientific) containing complete protease inhibitor cocktail (Roche) and phosphatase inhibitor (Thermo scientific) using a motor homogenizer (TH115, OMNI International). Samples were resolved by 7% or 4 -20% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (BioRad) on a semidry transfer apparatus. Immunoreactivity was detected by Immobilon chemiluminescent substrate (Thermo Scientific). Antibodies used were rabbit anti-NPC1 (1:2000, Abcam), mouse anti-Cre (1:1000, Millipore), rabbit anti-GFAP (1:5000, Dako), rabbit anti-Iba1 (1:2000, Wako) and rabbit anti-GAPDH (1:5000, Santa Cruz).
Histology
Mice were perfused with 0.9% normal saline followed by 4% paraformaldehyde. Brains and livers were removed and postfixed in 4% paraformaldehyde overnight. Brains were bisected, with the right hemisphere processed for paraffin embedding and the left hemisphere processed for frozen sections. Prior to freezing, brain tissue was cryoprotected in 30% sucrose for 48 h at 48C. Brains were frozen in isopentane chilled by dry ice and embedded in OCT (Tissue-Tek). Frozen sections were prepared at 14 mm in a cryostat and used for immunofluorescence staining for calbindin (1:1000, Sigma), GFAP (1:1000, Dako) and NeuN (1:500, Millipore). Sections were subsequently stained with filipin by incubating tissue sections for 90 min in phosphate buffered saline with 10% fetal bovine serum plus 25 mg/ml filipin (Sigma). For visualization of staining, secondary antibodies conjugated to Alexa Fluor 594 or Alexa Fluor 488 (Molecular Probes) were used and images were captured on a Zeiss Axioplan 2 imaging system. Paraffin-embedded sections were prepared at 5 mm and used for staining with H&E staining or Luxol fast blue, neurofilament (1:300, Covance) immunohistochemistry and Iba1 (1:1000, Wako) and GFAP (1:1000, Dako) immunofluorescence. Quantification of Purkinje cell loss was performed on H&E stained sections. Counts were normalized to the length of the Purkinje layer, as measured by NIH ImageJ software, and reported as Purkinje cell density.
Primary astrocyte culture
Cerebral hemispheres of 1-day-old mouse pups were dissected for the primary astrocyte culture described previously (39) . Tail DNA samples from pups were used for genotyping. After reaching confluence, cells were trypsinized and plated into 6-well plates for western blot, 12-well plates with cover slips for immunostaining and 96-well plates for XTT assay. Cells were subsequently treated with 5 mM 4-Hydroxytamoxifen (4-OHT, Sigma) after reaching 80% confluence, for four consecutive days to induce Cre-mediated gene deletion. On the following day (designated as 1 day post-deletion), cells were harvested for western blot or immunostaining. XTT assay was performed at different time points as indicated.
XTT assay
XTT assay was carried out using Cell Proliferation Kit II (XTT, Roche) according to the manufacturer's instructions with slight modifications. Briefly, 20 ml of XTT labeling mixture was added to each 96-well containing 100 ml medium. Cells were then incubated at 378C for 1 h, and the absorbance was measured at 490 nm with the reference at 650 nm.
Electrophysiology
Whole-cell recordings were obtained from Purkinje neurons in 300 mm parasagittal cerebellar slices prepared from 25-to 30-day-old mice. Vibratome sections were cut in ice-cold solution containing (in mM): 87 NaCl, 2. Na Phosphocreatine, 5 QX-314 and 10 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.3. Whole-cell recordings were made in ACSF containing 50 mM picrotoxin, 1 -5 h after slice preparation using an Axopatch 200B amplifier, Digidata 1400 interface and pClamp-10 software (Molecular Devices, Union City, CA, USA). Series resistance was compensated 50-70%. Cells were rejected if series resistance was .15 mV. EPSCs were recorded in voltage-clamp mode at a holding potential of 270 mV. EPSCs were evoked by applying square wave current pulses via a tungsten bipolar electrode to the molecular layer 100 mm from the Purkinje neuron of interest. Analog current traces were digitized at 100 kHz. EPSC decay time constants were obtained by fitting the current decay between 10 and 80% of the peak current amplitude to a single exponential as previously described (40) .
Statistics
Statistical significance was assessed by unpaired Student's t-test (for comparison of two means) or analysis of variance (ANOVA) (for comparison of more than two mean). The Newman -Keuls post hoc test was performed to carry out pairwise comparisons of group means if ANOVA rejected the null hypothesis. Statistics were performed using the software package Prism 5 (GraphPad Software). P-values ,0.05 were considered significant.
